通过调节Hippo-YAP活动,PRSS23促进胰腺癌的进展
Zhihong Liu1, Qiuping Jiang2, Yuanmeng Sun1
1Central Laboratory, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, 225300, China.
PRSS23是胰腺癌 (PDAC) 进展的关键驱动因素. 抑制PRSS23可能通过破坏Hippo信号通路和YAP激活为PDAC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 信号通道的信号通道
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种具有较低生存率的侵袭性癌症.
- 了解PDAC的分子驱动因素对于开发有效治疗方法至关重要.
研究的目的:
- 为了研究PRSS23在PDAC病变发生中的作用.
- 确定PRSS23的下游分子目标和参与PDAC的信号通路.
主要方法:
- 在PDAC组织中对PRSS23表达的临床分析.
- 在体外和体外功能实验 (敲击,扩散,转移分析).
- 转录基因分析,分子对接和共免疫沉以阐明信号机制.
主要成果:
- 在PDAC中,PRSS23过度表达,并与患者存活率降低有关.
- 抑制PRSS23抑制了PDAC细胞的增殖,瘤的生长和转移.
- PRSS23通过调节PP2A-MST1相互作用来调节Hippo信号通路,从而影响YAP活动.
结论:
- PRSS23是一种关键的瘤基因,也是PDAC的潜在预后生物标志物.
- PRSS23通过PP2A-MST1-YAP轴促进PDAC瘤发生和转移.
- 针对PRSS23/PP2A/MST1通路为PDAC提供了一个有前途的治疗途径.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
